TABLE 3.
Mutations and drug susceptibility in capreomycin-resistant M. tuberculosis clinical isolates
| Clinical isolate no. | Mutation
|
Drug susceptibilitya
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIC (μg/ml)b
|
INH | RIF | EMB | STR | CIP | ETH | ||||||
| tlyA | rrs | CAP | KAN | VIO | AMK | |||||||
| 1 | C insert in 218L | None | 80 | 20 | 20 | ≤4 | R | R | R | R | S | S |
| 10 | N236K | None | 80 | ≤5 | 20 | ≤4 | R | S | S | Rc | S | S |
| 21 | L150P | None | 40 | ≤5 | ≤10 | ≤4 | R | R | S | R | S | S |
| 22 | ΔA codon 23 | None | 80 | 20 | 40 | ≤4 | S | R | R | R | S | S |
| 11 | R14W | A1401G | >160 | >80 | >80 | >64 | R | R | R | R | S | R |
| 2 | None | A1401G | 80 | >80 | ≤10 | >64 | R | R | R | R | S | S |
| 3 | None | A1401G | 80 | >80 | ≤10 | >64 | R | R | R | R | R | S |
| 4 | None | A1401G | 20 | >80 | ≤10 | >64 | R | R | R | R | S | S |
| 5 | None | A1401G | 20 | >80 | ≤10 | >64 | R | S | S | R | S | S |
| 7 | None | A1401G | 40 | >80 | ≤10 | >64 | R | R | R | R | S | S |
| 9 | None | A1401G | >160 | >80 | 20 | >64 | R | R | R | R | S | R |
| 12 | None | A1401G | >160 | >80 | ≤10 | >64 | R | R | R | R | S | S |
| 13 | None | A1401G | >160 | >80 | 40 | >64 | R | R | R | R | S | S |
| 14 | None | A1401G | >160 | >80 | 40 | >64 | R | S | R | R | S | R |
| 15 | None | A1401G | >160 | >80 | 20 | >64 | R | R | R | R | R | R |
| 16 | None | A1401G | 20 | >80 | ≤10 | >64 | R | R | R | R | S | S |
| 17 | None | A1401G | 40 | >80 | 20 | >64 | R | R | S | R | S | R |
| 18 | None | A1401G | 20 | >80 | 20 | >64 | R | R | R | R | S | R |
a
R, resistant; S, susceptible; CAP, capreomycin; KAN, kanamycin; VIO, viomycin; AMK, amikacin; INH, isoniazid (5 μg/ml); RIF, rifampin; EMB, ethambutol; STR, streptomycin (10μg/ml); CIP, ciprofloxacin; ETH, ethionamide.
b
Control strains were susceptible to 10 μg of CAP/ml, 5 μg KAN/ml, 10 μg of VI O/ml, and 4 μg of AMK/ml.
c
Resistant to 2 μg of streptomycin/ml.